Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Gross Margin (2016 - 2019)

Aptevo Therapeutics' Gross Margin history spans 5 years, with the latest figure at 32.06% for Q4 2019.

  • For Q4 2019, Gross Margin changed N/A year-over-year to 32.06%; the TTM value through Dec 2019 reached 38.54%, changed N/A, while the annual FY2019 figure was 38.54%, 1284.0% down from the prior year.
  • Gross Margin for Q4 2019 was 32.06% at Aptevo Therapeutics, down from 56.06% in the prior quarter.
  • Across five years, Gross Margin topped out at 76.92% in Q1 2017 and bottomed at 98.97% in Q4 2015.
  • The 5-year median for Gross Margin is 43.61% (2016), against an average of 37.58%.
  • The largest annual shift saw Gross Margin surged 14104bps in 2016 before it crashed -2066bps in 2018.
  • A 5-year view of Gross Margin shows it stood at 98.97% in 2015, then surged by 143bps to 42.07% in 2016, then soared by 66bps to 69.67% in 2017, then fell by -17bps to 58.16% in 2018, then plummeted by -45bps to 32.06% in 2019.
  • Per Business Quant, the three most recent readings for APVO's Gross Margin are 32.06% (Q4 2019), 56.06% (Q3 2019), and 18.68% (Q2 2019).